ALLOX, a new Centre for Genomic Regulation spin-off, is launched with the support of Asabys
Home News ALLOX, a new Centre for Genomic Regulation spin-off, is launched with the support of Asabys

ALLOX, a new Centre for Genomic Regulation spin-off, is launched with the support of Asabys

DECEMBER 4, 2023 BHH Members Initiatives

ALLOX, a techbio company developing a proprietary technology to design new drugs targeting allosteric sites within oncology and other diseases, announces its incorporation today, as well as the successful closing of an undisclosed pre-seed financing from Asabys’ new fund Sabadell Asabys II.

ALLOX is a spin-off from the Centre for Genomic Regulation (CRG) in Barcelona, and is co-founded by Ben Lehner, Júlia Domingo, Pablo Baeza and Andre Faure. The company, with lab and office at the CRG/PRBB, has a unique systematic and scalable platform which can map allosteric sites in a large amount of proteins, including ‘undruggable’ or hard-to-target therapeutic targets.

Proteins are the effectors of molecular life. They interact with each other and the disruption of these interactions (so-called active sites) has been the main way of developing many of the current drugs on the market. Since nature is smart and highly resource-efficient, often these active sites are conserved in several proteins, which represents a drawback when you are trying to target a particular one. Often, targeting these interactions can have both a therapeutic and toxic effect, the main reason why many drugs never reach patients.

Lately, the search of selectivity has been fruitful thanks to the development of allosteric modulators. The term allostery means “other sites”. Allosteric sites are protein pockets, in which a molecule can bind, affecting the protein shape and indirectly blocking the protein-protein interactions that need to be targeted. Allosteric sites, in comparison with active ones, are often non-conserved and specific to each protein, so ensuring selectivity and safety. A holy grail for drug developers.

Yet, protein allosteric sites can be tough to find, and often very costly and time demanding. Many approaches have been developed computationally, very few experimentally, and almost none combining both experimental and computational ones, as ALLOX.

The ALLOX platform is based on ‘multidimensional mutagenesis’, an experimental method that allows measuring the activity of as many as 1 million mutant versions of a protein in a single experiment. The method is able to directly link genetic changes to phenotypical and finally biophysical measurements, which is something unprecedented. It is a tool for picking a needle in a haystack. This method allows to scan through, at the protein sequence level, and identify new allosteric pockets. Differently from other methodology, it is scalable, quick and cost efficient.

This financing by Sabadell Asabys will allow ALLOX to establish the initial team and facilities and to reach the level of validation and data that should trigger a new financial round in 18 to 24 months from now.

Asabys has successfully backed several other spin-offs and early-stage companies such as Ona Therapeutics, Origo Biopharma, SpliceBio, Inbrain Neuroelectronics, Nuage Therapeutics and OrikineBio.

Júlia Domingo, co-founder and CEO of ALLOX, comments: “A large portion of the therapeutic space is currently considered undruggable. Overcoming this challenge requires creating innovative and more intelligent therapeutics. ALLOX was founded with this mission in mind, convinced that the integration of massive high-throughput screening with AI will accelerate and revolutionise drug discovery. We feel fortunate and proud to embark on this exciting journey with Asabys.”

Ben Lehner, co-founder of ALLOX, adds: “I’m really happy that we have been able to found this company in Barcelona, the city in which this technology was developed. When we started this project it was pure blue skies research with no application. It was only much later that we realised the potential for drug development. It’s really exciting to see real world applications of our research. It’s also really interesting that there are now seven spin-out companies form the CRG and all seven of them have their foundations in basic non-translational research in genomics and computational biology. This blue skies research on foundational problems is where real innovation and new technology comes from.”

Clara Campàs, Managing Partner at Asabys, mentions “ALLOX’s outstanding technology and team have the potential to revolutionize the way we design and discover new and better medicines. We look forward to continuing working side by side with the founders to bring such innovation to patients”.

July 23, 2024 BHH Members Initiatives
Discover Anagram's Imaging CoreLab
Discover how Anagram's Imaging CoreLab plays an indispensable role in advancing clinical trials for stroke treatments through precision and innovation.
Read more
July 19, 2024 BHH Members Initiatives
Celebrating 10 Years of Innovation at The White Rabbit
The White Rabbit is excited to share their tenth anniversary with the Barcelona Health Hub ecosystem.
Read more
July 18, 2024 BHH Members Initiatives
Registration for BNEW Startup Hub Innovation 2024 is now open
Barcelona New Economy Week (BNEW) has opened the deadline to participate in the BNEW Barcelona Startup Innovation Hub to be held from 7 to 10 October 2024 as part of the fifth edition of BNEW.
Read more
July 15, 2024 BHH Members Initiatives
AI & mHealth Challenge 2024: Innovation in health and technology
GooApps is organizing the AI & mHealth Challenge 2024, an innovative event that will bring together health and technology professionals to solve challenges in the Spanish healthcare system with technological solutions.
Read more
July 11, 2024 BHH Members Initiatives
Ordering: Do me a video consultation with a sprinkle of chat
In this follow up blog, Webcamconsult delves into the parallels between the four pillars of e-commerce—viewing, ordering, payment, and delivery—from which healthcare can learn with regarding to e-health.
Read more
July 11, 2024 BHH Members Initiatives
Prescription apps for better healthcare: DiGA
Did you know that there are mobile apps created to be prescribed? Doonamis, experts in App development, explains what they are, how they work, and their benefits.
Read more
July 08, 2024 BHH Members Initiatives
Introducing Joppy: The smarter way to recruit tech talent
Are you a company that struggles with employer branding? Don't worry, Joppy gets it.
Read more
July 08, 2024 BHH Members Initiatives
Join the online training session on 'Virtual Reality in Pediatrics'
Join the online Pediatric Innovation Training Capsule session on 'Virtual Reality in Pediatrics' by i4Kids.
Read more
July 04, 2024 BHH Members Initiatives
Revolutionizing Parkinson's Care: Empowerment through Personalized Monitoring
LIFE Neurotech is dedicated to revolutionizing the management of Parkinson's disease by simplifying and enhancing accessibility for patients.
Read more
July 04, 2024 BHH Members Initiatives
Empowering Stroke Survivors: How New Technologies Transform Lives
Fundación Visible leads the effort to create projects that help understand and communicate conditions that alter people's quality of life.
Read more